Bicara Therapeutics - BCAX EV/Sales Multiple

Official company branding of Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc. (BCAX) brings together leading oncologists to combat solid tumors with the backing of major investors. Research continuity is ensured through certified biomaterial delivery channels. The company develops antibodies for head and neck cancer therapy, targeting the global market. The company's EV/Sales valuation demonstrates financial stability, with the metric value standing at 0.00.

Bicara Bio - BCAX EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for Bicara Therapeutics (BCAX)

Fundamental company valuation:Bicara Therapeutics Inc. BCAX
Product sample of bicara.com

The market values Bicara Therapeutics Inc. (BCAX) through the lens of its anti-cancer antibody development prospects. The EV/Sales metric compares the total enterprise value, adjusted for debt, against annual sales volume. This EV to revenue trend on the GURU.Markets platform visualizes market optimism regarding future earnings. For an R&D company, this indicator reflects investors' willingness to pay a premium for clinical trial potential. The stability of the multiple confirms the effectiveness of capital management following the IPO.

Competitor analysis for Bicara Therapeutics Inc.

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|Personalis, Inc. - Company Value to Revenue Ratio|Erasca - Company Value to Revenue|Business Value to Revenue DCTH|YMAB: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Aura Corp|CADL: EV/Sales Multiple|ARAY - Total Company Value-to-Revenue Ratio|SLS (SELLAS Life Sciences Group, Inc.) - EV/Sales Multiple|ACTU: Business Value to Revenue|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio